Moreover, cancers with MT K-Ras are more aggressive [5] and resistant to targeted therapies such as anti-EGFR (epidermal growth factor receptor) [6, 7] and MAPK kinase (MEK) inhibitors [8, 9]. This evidence concerns the gene EGFR and cancer.